18F-FDG hPET/CT显像对肿瘤的诊断价值

目的探讨18F-脱氧葡萄糖(FDG)hPET/CT显像在肿瘤诊断中的价值.方法对27例经病理组织学或临床诊断的恶性肿瘤患者(包括15例原发性肿瘤、12例转移性肿瘤)和33例良性病变(18例甲状腺腺瘤、7例桥本氏甲状腺炎和8例肺部良性肿瘤)进行18F-FDG hPET/CT显像,勾画病灶感兴趣区(ROI),在对侧相应位置复制相同大小ROI,测定计数得靶/非靶比值(T/N),并对良恶性病变的T/N比值进行比较.结果27例恶性肿瘤患者中(T/N比值为10.47±8.22),22例FDG显像示单个或多处呈不同程度异常浓聚灶,5例未见异常FDG浓聚灶.33例良性病变中(T/N比值4.51±12.14),10例见病变处FDG异常摄取增高.以T/N比值≥2.0作为判断良恶性病变的标准,18F-FDG hPET/CT诊断的灵敏度为81.48%,特异性为69.70%,准确性为75.00%,阳性预测值为68.75%,阴性预测值为82.14%.结论18F-FDG hPET/CT显像对肿瘤良恶性鉴别、解剖定位的判断、分期及疗效观察具有一定的优势.     

18F-FDG PET显像诊断肾上腺肿瘤

目的　评价1 8F 脱氧葡萄糖 (FDG)PET显像对肾上腺肿瘤的诊断价值。方法　对 2 1例肾上腺肿瘤患者共 2 2个肾上腺病灶行1 8F FDGPET显像 ,对显像结果进行定性和半定量分析 ,并与CT和 (或 )MRI、针刺活组织检查、术后病理检查结果进行对比研究。结果　 9例肾上腺病灶处无明显FDG浓集 ,PET显像诊断为良性病变 ;12例病灶处FDG明显浓集 ,诊断为恶性病变。与病理检查结果比较 ,PET显像定性准确性为 10 0 % ,CT和 (或 )MRI为 6 4 %。良性病变与周围正常组织 (T N)放射性比值为 0 3～ 1 3,平均为 0 7,标准摄取值 (SUV)为 0 98～ 3 89,平均为 1 89;恶性病变T N比值为 3 1～15 1,平均为 6 9,SUV为 3 10～ 15 5 2 ,平均为 6 4 1,两组间差异均有显著性 (P均 <0 0 0 1)。病变性质与肿块大小无相关性。其中 4例PET显像发现了CT和 (或 )MRI未发现的局部淋巴结和远处转移灶12处。结论　1 8F FDGPET显像对肾上腺肿瘤定性诊断的准确性明显高于CT和 (或 )MRI。     

SPECT/CT双探头符合线路衰减与非衰减校正在肿瘤诊断中的应用

目的　评价SPECT CT双探头符合线路衰减和非衰减校正技术对肿瘤诊断的意义。方法　用1 8F 脱氧葡萄糖 (FDG)SPECT双探头符合线路显像 ,经衰减和非衰减校正测量病灶的靶与本底 (L B)比值。结果　①衰减校正检出恶性病变 4 1例 (5 6个病灶 )、良性病变 7例 (11个病灶 ) ;非衰减校正检出的良恶性病变部位和数量与衰减校正一致。②经衰减校正检出的 5 6个恶性病灶L B比值为 2 4 .0 7～ 1.39,平均 5 .2 0± 4 .2 8,其中 <2 .0为 8个 ,2 .0～ 2 .5为 7个 ,>2 .5为 4 1个 ;良性病灶 11个 ,L B比值为 2 0 .1～ 1.4 8,平均 5 .6 1± 4 .79,其中 <2 .0为 2个 ,2 .0～ 2 .5为 2个 ,>2 .5为 7个。③经衰减校正良恶性病灶L B比值平均为 5 .2 8± 3.5 1,非衰减校正为 3.2 2± 2 .0 0 ,两者间差异无显著性(P >0 .0 5 ) ,且呈正相关 (r =0 .77,P <0 .0 1)。结论　1 8F FDGSPECT双探头符合线路显像中衰减和非衰减校正对检出病灶数量和定位无明显区别 ,但前者图像明显好于后者。仅据L B比值判断良恶性病变不可靠。     

99Tcm-MIBI亲肿瘤延迟断层显像对肺占位病灶的诊断价值

目的 探讨99Tcm-MIBI亲肿瘤延迟断层显像在肺部占位病灶中的诊断价值.方法 对28例肺部占位患者静脉注射740 MBq99Tcm-MIBI后1 h行延迟断层显像,以占位病灶(T)/对侧相应部位或邻近正常组织(N)的摄取比值T/N＞1.31为恶性病变标准对肺部占位病灶进行良、恶性判断.结果 肺占位在良性占位组显像剂浓聚多数轻度增强,恶性占位组多数明显增强.肺占位诊断恶性病灶的灵敏度为76.9%,特异度为86.7%,假阳性为13.3%,假阴性为23.1%.结论 99Tcm-MIBI亲肿瘤延迟断层显像以其无创、灵敏、图像质量及特异性较高的优点,可作为在肺占位病灶良、恶性鉴别诊断的重要辅助检查手段.     

99Tcm-HL91肺癌显像的临床应用

目的 探讨~(99)Tc~m-4,9-二氮-3,3,10,10-四甲基十二烷-2,11-二酮后(HL91)显像对肺部肿瘤定性的价值。方法 对32例肺部肿瘤患者注射~(99)Tc~m-HL91后10 min,2、4 h进行显像,将显像结果分为~(99)Tc~m-HL91显像阳性组和阴性组,对~(99)Tc~m--HL91显像阳性患者利用感兴趣区(ROI)技术分别勾画各时相肿瘤(T)与对侧相应部位(N)ROI,计算T/N比值。所有患者均经手术病理检查证实,将显像结果与CT和病理检查结果对照。结果 ~(99)Tc~m-HL91显像灵敏度为82.6％,特异性为100％,准确性为87.5％。CF灵敏度为69.6％,特异性为100％,准确性为78.1％。CT提示肺癌16例中,~(99)Tc~m-HL91显像均阳性。随~(99)Tc~m-HL91显像时间延长,T/N比值增高,10 min为1.620±0.320,2 h为1.737±0.416,4 h为1.909±0.491。10 min与2 h差异无显著性(P>0.05),10 min与4 h差异有显著性(P<0.05)。肺腺癌组与肺鳞癌组各时相T/N比值差异无显著性(P>0.05)。结论 ~(99)Tc~m-HL91显像判断肺肿瘤良恶性有较好价值。     

11C-胆碱PET/CT显像在前列腺良恶性病变鉴别诊断中的应用

目的 探讨11C-胆碱PET/CT显像在前列腺良恶性病变鉴别诊断中的作用.方法 前列腺病变患者45例,按体重静脉注射7.4 MBq/kg 11C-胆碱5 min后行仰卧位盆腔PET/CT显像,可疑转移患者行全身显像.测量前列腺病灶(靶)及肌肉(非靶)组织的最高标准摄取值(SUVmax),并计算其比值(P/M).结果 病理检查证实前列腺良性病变27例,前列腺癌18例.前列腺良恶性病变的P/M比值间差异有显著性(1.87±1.21与4.02±1.88,t=2.07,P＜0.01).以P/M比值＞2.32为标准,11C-胆碱PET/CT显像诊断前列腺癌的灵敏度为88.89%,特异性为88.89%,阴性预测值为92.31%.结论 11C-胆碱PET/CT显像是一种诊断前列腺癌较好的无创性检查方法;P/M比值比SUV能更好鉴别前列腺良恶性病变.     

18 F-FDG PET对肺癌的诊断及鉴别诊断

目的　探讨1 8F 脱氧葡萄糖 (FDG)PET显像对肺癌诊断、鉴别诊断的临床价值。方法181例患者分为肺癌组和肺部良恶性病变鉴别组 ,均行1 8F FDGPET显像。分析病灶的标准摄取值(SUV)及其形态学表现。结果　①肺癌组 79例 ,有 78例可见1 8F FDG浓聚 ,SUV =4.19± 1.66,其中 9例SUV <2 .5 ,6例SUV <2 .0。 93 .6%病灶表现为结节状或团块状 ,7例病灶内有放射性缺损者 ,缺损影周围组织多数浓聚程度高且较厚 ,3 5例病灶边缘呈分叶状。②肺部良恶性病变鉴别组 10 2例 ,其中确诊为肺癌的 60例患者病灶均表现为1 8F FDG高摄取 ,SUV为 4.5 7± 1.73 ;形态学表现与肺癌组一致。确诊为良性病变的 42例患者 ,病灶多表现为放射性浓聚程度低或不显影 ,SUV为 1.5 1± 1.0 5 ,与肺癌组比较差异有显著性 (P <0 .0 1)。形态学表现多样化。 6例SUV >2 .5良性病变中 ,有 2例呈片状和斑片状 ,与肺癌病灶形态有一定差异。 10 2例患者中采用SUV >2 .5、SUV >2 .5结合形态分析和SUV >2 .0结合形态分析用于诊断肺癌 ,灵敏度、特异性及准确性相近 ,后 2种方法诊断效能稍高于单用SUV >2 .5法 ,但差异无显著性 (P >0 .0 5 )。结论　1 8F FDGPET显像对肺癌诊断及鉴别诊断有较好的诊断效能。SUV结合形态学分析有助于病灶的鉴别诊断     

双时相PET显像在肺良恶性病变鉴别诊断中的应用

目的　评价双时相显像在肺部结节良恶性鉴别诊断中的应用价值。方法　对 3 2例肺癌患者和 15例肺良性病变患者进行1 8F 脱氧葡萄糖 (FDG)PET双时相显像 ,早期显像于注射FDG后40～ 65min ,延迟显像于注射后 1.5～ 2 .5h进行 ,测定两次显像病灶的标准摄取值 (SUV) ,并计算两次显像SUV变化率 (ΔSUV)。结果　肺癌组早期显像SUV为 4.3 2± 2 .5 9,延迟显像为 6.71± 4.2 6,ΔSUV为 ( 5 4.5 9± 2 8.96) %。而肺部良性病变早期显像SUV为 2 .83± 1.3 6,延迟显像为 3 .3 1± 1.95 ,ΔSUV为 ( 18.11± 2 5 .3 9) %。结论　双时相显像方法简便 ,在临床上具有一定的实用价值。肺恶性病变延迟显像SUV升高的幅度高于良性病变 ,但结核及炎性肉芽肿延迟显像SUV可增高     

用ROC曲线法分析99Tcm-HL91肺肿瘤阳性显像的诊断效能

目的探讨半定量分析及接受器工作特性(ROC)曲线法在99Tcm-4,9-二氮-3,3,10,10-四甲基十二烷-2,11-二酮肟(HL91)肿瘤阳性显像鉴别肺部良恶性肿块中的价值.方法经CT检查发现肺部肿块的患者50例,均经活组织检查或手术病理检查证实.根据病理检查结果分为恶性组37例和良性组13例.术前行99Tcm-HL91 2 h、4 h平面显像及4 h断层显像,分别使用视觉判断法、半定量分析及ROC曲线法分析显像结果.结果①视觉判断法99Tcm-HL91显像的灵敏度、特异性和准确性分别为97.3%、69.2%和90.0%.②肿瘤/正常肺组织(T/N)比值半定量分析及ROC曲线法恶性组2 h、4 h平面显像及4 h断层显像T/N比值分别为1.52±0.19、1.73±0.28及2.84±0.97;良性组分别为1.20±0.16、1.24±0.20及1.52±0.40.各个时相的曲线下面积分别为0.909±0.056、0.945±0.039、0.953±0.034.从99Tcm-HL91断层显像ROC曲线的界值点找到1个界点(T/N=1.76),以其作为判断良、恶性的诊断阈值,灵敏度、特异性和准确性分别为100%、84.6%和96.0%.③视觉判断法与半定量分析法比较T/N比值半定量分析及ROC曲线法使诊断的灵敏度、特异性和准确性都有提高,尤其特异性.但两种方法间差异无显著性(P均＞0.05).结论半定量分析及ROC曲线法的诊断阈值可进一步提高99Tcm-HL91肺部肿瘤阳性显像的诊断效能.     

肺良恶性病变99Tcm-MIBI显像与肺癌DNA含量分析

目的探讨99Tcm-甲氧基异丁基异腈(MIBI)诊断肺部良恶性病变的价值及肺癌摄取99Tcm-MIBI比值与癌细胞DNA含量的关系.方法 27例肺良性病变及46例肺恶性病变患者均行99Tcm-MIBI早期和延迟肺显像,并测定病变靶/非靶(T/NT)摄取比值(UR).对肺恶性病变组中的24例手术标本进行DNA含量测定,计算DNA含量指数(DI),并与术前99Tcm-MIBI UR进行相关分析.结果良性病变组延迟UR为1.13±0.19,肺癌组为1.45±0.21,两者比较P<0.01;延迟相目测观察及UR诊断肺癌的灵敏度、特异性、准确性分别为91.3%,55.6%,78.1%和80.4%,62.9%,73.9%;正常支气管黏膜上皮(二倍体)细胞DI=0.68±0.21,肺腺瘤DI=0.51±0.27,肺癌组DI=1.43±0.33(与前两者比较,P均<0.01).肺癌组异倍体细胞出现率为83.3%.肺癌组DI与延迟UR的r为0.32.结论 99Tcm-MIBI不是理想的鉴别诊断肺部良恶性病变的显像剂;延迟相UR有可能间接反映癌细胞DNA含量.     

螺旋CT扫描成像质量分析

目的：通过对螺旋与常规ＣＴ扫描的比较，图像的分析和讨论，以期为临床诊断提供有用的依据。材料和方法：螺旋及常规ＣＴ扫描采用Ｓｏｍａｔｏｍ Ｐｌｕｓ全身ＣＴ扫描机。扫描体模：（１）玻璃球，直径１．５ｃｍ，误差〈１０μｍ；（２）有机圆柱体，直径３．０ｃｍ，误差〈８μｍ；（３）水模，直径２５ｃｍ。扫描条件相同情况下，在下述方面进行比较：（１）不同物体螺旋ＣＴ扫描图像还原性的影响；（２）不同螺距扫描与图像分     

Choroidal and retinal anatomical response following treatment of carotid-ophthalmic aneurysms with flow diverter stents

BackgroundFlow diverter stents(FDSs) are recent additions to the endovascular armament for treating ophthalmic segment aneurysms(OSA). In our study we evaluated the long-term effect of FDS placement on multiple Optical Coherence Tomography(OCT) findings, best corrected visual acuity(BCVA) and intra-ocular pressure(IOP).MethodsA prospective cohort study was conducted in 35 patients treated with a single FDS placement for OSA, between 2013 and 2018. Spectral-domain OCT was used to measure retinal nerve fiber layer thickness, ganglion cell complex thickness, subfoveal choroidal thickness(SFCT), and other stereometric parameters. Choroidal Vascularity Index(CVI) in a 1.5 mm wide subfoveal choroidal area was calculated. BCVA and IOP were also assessed. These measurements, at final follow up, were compared to the untreated fellow eye to evaluate the long-term effect of FDS placement.ResultsThis study included 70 eyes from 35 patients (100% female) with a mean age of 54.9 ± 9.8 years and mean follow-up period of 37.3 ± 18.9 months. No ophthalmic artery occlusion was encountered. The mean CVI was significantly higher in the stented side compared to the fellow normal eye (66.90±1.95 vs 65.05±1.93, p=.001) while mean SFCT was significantly reduced (251.23±68.54 vs 288.78±78.95, p=.037). Differences in the remaining studied parameters did not reach statistical significance. The difference in BCVA between stented and fellow normal eyes was also not significant (0.057±0.213 vs 0.060±0.214, p=.977 in logMAR).ConclusionTreatment with FDSs did not cause permanent visual damage. This study is the first to report a decrease in SFCT with a compensatory increase in CVI following FDS placement for OSA.     

Factors effecting the choroidal vascularity index in children with mild to moderate myopia

PurposeTo measure the choroidal structural parameters in a population of myopic children and determine the factors effecting the choroidal vascularity index (CVI).Methods:In total, 200 eyes of 200 children (100 females, 100 males) with a mean age of 11.5 ± 1.6 years were included in the study. Macular imaging was performed using EDI mode of spectral domain-optical coherence tomography. Binarization of the choroidal area was performed with ImageJ software. Total choroidal area, luminal area (LA), stromal area (SA), and CVI were automatically calculated.ResultsThe mean choroidal, stromal and luminal areas were measured as 0.952 ± 0.127 mm², 0.626 ± 0.103 mm² and 0.325 ± 0.076 mm², respectively. The mean CVI was 65.81% ± 6.56. Age and the axial length (AL) of the participants were not found to be associated with the LA and the CVI. (r=-0.078, p=0.274, r=0.017, p=0.808, and r=0,051, p=0.474 and r=-0.128, p=0.071, respectively). There was a statistically significant strong association between the LA and CVI measurements and SE of the participants (r=0.736, p=0.001, and r=-0.605; p=0.001).ConclusionAge and AL were not associated with the CVI, but SE was significantly associated with the CVI.     

Hydroxychloroquine treatment alters retinal layers and choroid without apparent toxicity in optical coherence tomography

Background To investigate whether single retinal layer, choroidal and peripapillary retinal fiber layer thicknesses were affected in patients under hydroxychloroquine treatment without retinal toxicityMethods Forty-nine patients under hydroxychloroquine treatment (HCQ group) and 39 healthy volunteers, a total of 88 individuals, were included in the study. Patients with HCQ treatment were further divided into two groups as less than 5 years of HCQ use (group 1, 29 patients) and 5 years or more of HCQ use (group 2, 20 patients). All participants underwent full ophthalmologic examination and optical coherence tomography (OCT) imaging as OCT is a recommended tool for screening toxicity by the American Association of Ophthalmology. The automatic segmentation of retinal layers included retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear layer (ONL), retina pigment epithelium (RPE), inner retinal layers (IRL), outer retinal layers (ORL) and total retina thickness (TRT). Choroidal thickness (ChT), choroidal vascularity index and peripapillary RNFL were also measured.Results Both inferior and nasal parafoveal RNFL, temporal parafoveal GCL, and IPL layer thicknesses were decreased, while temporal parafoveal RPE layer thicknesses were increased in hydroxychloroquine users. Subfoveal ChTs were significantly reduced in both groups 1 and 2 compared to the control group(p = 0.042 and p = 0.009, respectively) and temporal ChT thicknesses were statistically decreased in group 2 compared to the control group(p = 0.018), but not for nasal ChT.Conclusions Hydroxychloroquine use may cause parafoveal retinal layer thickness alterations and also subfoveal and parafoveal ChT alterations even without evident retinal toxicity in OCT.     

PET/CT与HRCT在孤立型细支气管肺泡癌诊断中的协同应用价值

目的探讨正电子发射计算机体层成像(PET/CT)与高分辨率CT(HRCT)在孤立型细支气管肺泡癌(sol-itary bronchioloalveolar carcinoma,SBAC)诊断中协同应用的价值,以提高对该病的诊断准确率。方法搜集经手术病理证实的28例SBAC患者的PET/CT及HRCT影像资料,患者均先行PET/CT显像,其中16例根据诊断需要于0～3天内行HRCT检查,分析两者对SBAC的协同诊断价值。结果 28例中,PET/CT显像确切诊断肺癌者15例(53.6%),恶性不除外5例(17.9%),良性病变8例(28.6%),误诊率较高。16例HRCT协同PET/CT确切诊断肺癌15例,其中1例初诊良性病变,后经HRCT结合图像后处理技术诊断为肺癌,1例伴右肺门淋巴结转移者,HRCT图像仅显示形态正常淋巴结影,而PET/CT诊断淋巴结转移,后经病理证实;PET/CT与HRCT协同诊断正确率达100%。结论 PET/CT显像诊断SBAC易出现假阴性,误诊率较高;PET/CT与HRCT在SBAC诊断中的协同应用能够弥补常规PET/CT显像中的不足,达到优势互补并充分发挥PET/CT的资源优势,有助于提高对SBAC的诊断准确率。     

PET及PET-CT在放射治疗计划中的应用价值

肿瘤放射治疗已进入PET及PET-CT引导的生物适形治疗时代,PET及PET-CT改进和优化了综合治疗计划的实施,改进了放疗计划的实施目的,精确了肿瘤放疗靶区的制定,同时在靶区勾画过程中大大减少了不同医生所勾画靶区的差异,并减少了勾画靶区的偏倚,通过准确靶区范围而使治疗-效益比提高.     

发作间期PET显像与发作期SPECT显像在癫痫灶定位中的应用

目的：探讨发作间期PET显像与发作期SPECT显像在癫痫灶定位中的特点和相关性。方法：对54例癫痫患者行发作间期PET和发作期SPECT2次检查,对结果进行对比分析。结果：54例发作间期PET显像示低代谢者中33例（61．1％）表现为单叶局限性低代谢,21例（38．9％）表现为多个病灶或弥漫性改变。发作期SPECT显像50例可见高灌注灶,高灌注中37例（74％）为单叶局限性高灌注,13例（26％）为多个病灶,未见弥漫性高灌注。2项检查比较,46例（85．2％）2项检查结果相符合,其中32例（69．6％）显示为颞叶病灶。发作间期PET示多病灶及弥漫性改变者于发作期SPECT为像时为9例（42．9％）转化为单叶局限性病灶,7例（33．3％）排除了部分低代谢病灶。结论：癫痫灶灌注与代谢改变具有明显的相关性。发作间期PET显像定位癫痫灶解剖结构显示较为清晰,发作期SPECT显像替代发作期PET检查可提高定位特异。2项检查联合应用可排除非致痫性病变和发作过程中痫性电活动的泛化,具有较好的互补性。     

18F-FDG PET-CT在卵巢癌术后监测中的应用

目的:探讨18氟-脱氧葡萄糖(18F-FDG)正电子发射计算机体层摄影(PET-CT)在卵巢癌术后监测中的应用价值。方法:16例卵巢癌患者经肿瘤细胞减灭术和术后化疗或放疗,临床完全缓解6个月以上。行18F-FDG PET-CT检查,结果与手术病理结果对照。结果:18F-FDG PET-CT发现了9例患者,有复发或转移,共发现病灶直径0.3~3.2cm 23处病灶。手术病理证实9例(56%)无假阳性,无假阴性,诊断准确率100%;诊断复发或转移灶的敏感性、特异性、准确率、阳性预测值和阴性预测值分别为78%、78%、78%、90%和58%。PET-CT显示与术中所见病灶的大小、部位均一致。结论:18F-FDGPET-CT在卵巢癌的术后监测中有很高的诊断价值。     

The effect of branch retinal vein occlusion on the vascular structure of the choroid

ObjectiveOur aim is to examine choroidal structural changes in eyes with branch retinal vein occlusion (BRVO).Material and MethodThis retrospective, comparative study included 34 newly diagnosed unilateral BRVO patients and 40 healthy controls. Subfoveal choroidal thickness (SFCT) measurement was performed with enhanced depth imaging optical coherence tomography (EDI-OCT). The images were binarized using the ImageJ software program. Total choroidal area (TCA), stromal area (SA), and luminal area (LA) were calculated from the 1500 µm area. The choroidal vascular index (CVI) was determined as the LA/TCA ratio. All parameter values were compared between the BRVO eye and the fellow eye, and the control group eyes.ResultsEyes with BRVO had a greater SA compared to both fellow and control eyes; hence, the CVI was lower (p < 0.001). LA did not differ between eyes. TCA, although not statistically significant, was larger in eyes with BRVO than in both fellow and control eyes. SFCT was also greater in eyes with BRVO. No correlation was observed between CVI and SFCT and best-corrected visual acuity (BCVA).ConclusionBRVO affects the stromal part of the choroid rather than its vascular structure. SA increases due to choroidal exudation that occurs in response to retinal ischemia, and CVI decreases accordingly.     

18F-FDG PET/CT显像联合HRCT对孤立性原发肺浸润性黏液腺癌的诊断价值

目的探讨孤立性原发肺浸润性黏液腺癌18F-FDG PET/CT显像和HRCT征象及两者联合对该病的诊断价值。方法回顾性分析经病理证实为浸润性黏液腺癌、有18F-FDG PET/CT双时相显像及病灶层面同机HRCT扫描资料的9例患者,对PET/CT早期、延迟显像及滞留指数、HRCT征象进行综合分析。结果HRCT图像上表现为2例呈实性结节、病灶周围无类似卫星灶样影,6例实性结节周围伴小点片及磨玻璃样影,1例为单纯磨玻璃样结节;分叶征(6例)、血管集束征(6例)、支气管充气征(4例)、空泡征(2例)、毛刺征(1例);18F-FDG PET/CT融合图像上8例病灶表现为不均匀FDG代谢增高,早期显像平均SUVmax为3.2±2.5,延迟现象SUVmax增高6例、降低2例,平均SUVmax为3.5±2.4,平均滞留指数为(10.4±29.3)%,9例均未见纵隔、双侧肺门淋巴结及其他部位转移征象,其18F-FDG PET/CT融合图像上18F-FDG摄取与HRCT相匹配,18F-FDG摄取相对集中于结节的实性区域,病灶磨玻璃区18F-FDG摄取不明显;综合手术病理结果等临床资料证实,9例均为T1N0M0期,与PET/CT分期一致。结论对于影像学检查发现肺孤立性占位患者,在单一影像学检查难以明确诊断的情况下,18F-FDG PET/CT双时相显像上病灶不均匀18F-FDG摄取相对集中于其实性区域的代谢方式与HRCT相联合,可辅助孤立性原发性肺浸润性黏液腺癌的诊断。